MXPA04004368A - Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos. - Google Patents
Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos.Info
- Publication number
- MXPA04004368A MXPA04004368A MXPA04004368A MXPA04004368A MXPA04004368A MX PA04004368 A MXPA04004368 A MX PA04004368A MX PA04004368 A MXPA04004368 A MX PA04004368A MX PA04004368 A MXPA04004368 A MX PA04004368A MX PA04004368 A MXPA04004368 A MX PA04004368A
- Authority
- MX
- Mexico
- Prior art keywords
- enantiomerically enriched
- citalopram
- methods
- didesmethyl
- desmethyl
- Prior art date
Links
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical class C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 title abstract 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229960003638 dopamine Drugs 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960002748 norepinephrine Drugs 0.000 abstract 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 2
- 230000000697 serotonin reuptake Effects 0.000 abstract 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
- C07D317/20—Free hydroxyl or mercaptan
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invencion se refiere a composiciones novedosas de materia que contiene (-)-desmetilcitalopram enantiomericamente enriquecido, (+)-didesmetilcitalopram, o (-)-didesmetilcitalopram o mezclas de los mismos en relaciones optimas; de manera contraria a las ensenanzas anteriores, los metabolitos de citalopram enantiometicamente enriquecidos descritos en la presente invencion poseen una potente actividad inhibidora de la retoma de serotonina,, con efectos inhibidores minimos sobre la retoma de otras monoaminas conocidas, por ejemplo, norepinefrina (NE) o dopamina (DA); la presente invencion tambien describe metodos para tratar trastornos, disfunciones y enfermedades para las cuales la inhibicion de la retoma de serotonina es terapeuticamente benefica; en particular, la presente invencion describe metodos para tratar diversas formas de depresion con composiciones farmaceuticas descritas en la presente invencion.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33760801P | 2001-11-08 | 2001-11-08 | |
| PCT/US2002/035408 WO2003040121A1 (en) | 2001-11-08 | 2002-11-05 | Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04004368A true MXPA04004368A (es) | 2004-08-11 |
Family
ID=23321236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04004368A MXPA04004368A (es) | 2001-11-08 | 2002-11-05 | Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040266864A1 (es) |
| EP (1) | EP1446396A1 (es) |
| JP (1) | JP2005510518A (es) |
| KR (1) | KR20050043776A (es) |
| CN (1) | CN1705654A (es) |
| AU (1) | AU2002356903A2 (es) |
| BR (1) | BR0213949A (es) |
| CA (1) | CA2465186A1 (es) |
| HU (1) | HUP0401934A3 (es) |
| IL (1) | IL161617A0 (es) |
| MX (1) | MXPA04004368A (es) |
| NO (1) | NO20042013L (es) |
| NZ (1) | NZ532478A (es) |
| PL (1) | PL368452A1 (es) |
| RU (1) | RU2004117211A (es) |
| WO (1) | WO2003040121A1 (es) |
| ZA (1) | ZA200403409B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ561375A (en) | 2005-06-27 | 2011-06-30 | Biovail Lab Int Srl | Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound |
| EP1928450A2 (en) * | 2005-08-26 | 2008-06-11 | Xenoport, Inc. | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
| US20080161393A1 (en) * | 2006-12-08 | 2008-07-03 | Barrett Ronald W | Use of prodrugs of GABA analogs for treating disease |
| KR101103118B1 (ko) * | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| US9056850B2 (en) | 2008-10-17 | 2015-06-16 | Janssen Pharmaceutica N.V. | Process for the preparation of compounds useful as inhibitors of SGLT |
| RU2488390C2 (ru) * | 2008-12-29 | 2013-07-27 | Тартуский Университет | Ингибиторы аргиназы для лечения депрессии |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| DK2488515T3 (en) | 2009-10-14 | 2017-02-27 | Janssen Pharmaceutica Nv | PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2 |
| EP2377522B1 (en) * | 2010-04-15 | 2013-01-16 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Orally disintegrating tablet formulations of mirtazapine and process for preparing the same |
| ES2596291T3 (es) | 2010-05-11 | 2017-01-05 | Janssen Pharmaceutica, N.V. | Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt |
| PT2697218T (pt) | 2011-04-13 | 2016-07-13 | Janssen Pharmaceutica Nv | Processo para preparação de compostos úteis como inibidores da sglt2 |
| KR101427221B1 (ko) * | 2012-08-29 | 2014-08-13 | 주식회사 에스텍파마 | 플루복사민 자유 염기의 정제방법 및 이를 이용한 고순도 플루복사민 말레이트의 제조방법 |
| PT3256466T (pt) * | 2015-02-11 | 2022-05-10 | Sunovion Pharmaceuticals Inc | Compostos e análogos de 1-heterociclilo isocromanil para tratamento de distúrbios do snc |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805812A1 (fr) * | 2000-02-24 | 2001-09-07 | Lundbeck & Co As H | Procede de preparation du citalopram |
| IES20010157A2 (en) * | 2000-03-03 | 2002-03-06 | Lundbeck & Co As H | Method for the preparation of citalopram |
| CZ20023100A3 (cs) * | 2000-03-13 | 2003-02-12 | H. Lundbeck A/S | Způsob výroby citalopramu |
| TR200201166T1 (tr) * | 2000-12-22 | 2002-10-21 | H.Lundbecks A/S | Saf sitalopram hazırlanması için yöntem |
-
2002
- 2002-11-05 BR BR0213949-9A patent/BR0213949A/pt not_active IP Right Cessation
- 2002-11-05 CN CNA028220846A patent/CN1705654A/zh active Pending
- 2002-11-05 RU RU2004117211/04A patent/RU2004117211A/ru not_active Application Discontinuation
- 2002-11-05 JP JP2003542167A patent/JP2005510518A/ja not_active Withdrawn
- 2002-11-05 NZ NZ532478A patent/NZ532478A/en unknown
- 2002-11-05 PL PL02368452A patent/PL368452A1/xx unknown
- 2002-11-05 KR KR1020047006982A patent/KR20050043776A/ko not_active Application Discontinuation
- 2002-11-05 HU HU0401934A patent/HUP0401934A3/hu unknown
- 2002-11-05 IL IL16161702A patent/IL161617A0/xx unknown
- 2002-11-05 AU AU2002356903A patent/AU2002356903A2/en not_active Abandoned
- 2002-11-05 MX MXPA04004368A patent/MXPA04004368A/es unknown
- 2002-11-05 CA CA002465186A patent/CA2465186A1/en not_active Abandoned
- 2002-11-05 EP EP02802848A patent/EP1446396A1/en not_active Withdrawn
- 2002-11-05 WO PCT/US2002/035408 patent/WO2003040121A1/en not_active Application Discontinuation
-
2004
- 2004-05-05 ZA ZA200403409A patent/ZA200403409B/xx unknown
- 2004-05-07 US US10/842,055 patent/US20040266864A1/en not_active Abandoned
- 2004-05-14 NO NO20042013A patent/NO20042013L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL368452A1 (en) | 2005-03-21 |
| NO20042013L (no) | 2004-05-14 |
| EP1446396A1 (en) | 2004-08-18 |
| US20040266864A1 (en) | 2004-12-30 |
| NZ532478A (en) | 2007-02-23 |
| CA2465186A1 (en) | 2003-05-15 |
| IL161617A0 (en) | 2004-09-27 |
| HUP0401934A3 (en) | 2007-05-29 |
| BR0213949A (pt) | 2004-08-31 |
| WO2003040121A1 (en) | 2003-05-15 |
| ZA200403409B (en) | 2005-10-26 |
| KR20050043776A (ko) | 2005-05-11 |
| HUP0401934A2 (hu) | 2005-01-28 |
| JP2005510518A (ja) | 2005-04-21 |
| CN1705654A (zh) | 2005-12-07 |
| AU2002356903A2 (en) | 2003-05-19 |
| RU2004117211A (ru) | 2005-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2001062257A3 (en) | Bupropion metabolites and methods of their synthesis and use | |
| MXPA04004368A (es) | Metodos para tratar depresion y otros transtornos del sistema nervioso central utilizando desmetil-y didesmetil-metabolitos del citalopram enantiomericamente enriquecidos. | |
| WO2000051546A3 (en) | Bupropion metabolites and methods of their synthesis and use | |
| CA2364718A1 (en) | Monoamine reuptake inhibitors for treatment of cns disorders | |
| HUP0201623A3 (en) | Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system | |
| WO2002041889A3 (en) | Indolsulfonyl compounds useful in the treatment of cns disorders | |
| WO2002053140A3 (en) | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents | |
| WO2002038142A3 (en) | Serotonergic compositions and methods for treatment of mild cognitive impairment | |
| WO2004047830A3 (de) | Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen | |
| MY135696A (en) | Pyrrolidone derivatives as maob inhibitors | |
| WO2003037368A3 (en) | Smad7 inhibitors for the treatment of cns diseases | |
| MX2007006754A (es) | Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos. | |
| GB0420831D0 (en) | Novel compounds | |
| BG105218A (en) | The use of optically pure (+) norcisapride for treating gastro-esophageal reflux disease | |
| BG103949A (en) | A new salt | |
| HUP0101326A2 (hu) | Paroxetinkompozíciók és eljárás az előállításukra | |
| HK1068878A1 (en) | Novel 2, 5-diazabicyclo Ä2.2.1Üheptane derivatives | |
| SE9803155D0 (sv) | A new composition | |
| HUP0102298A2 (hu) | Paroxetin-10-kámforszulfonát központi idegrendszeri rendellenességek kezelésére és eljárás az előállítására | |
| UA88284C2 (ru) | Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения | |
| WO2004056821A3 (en) | Quinolizidine derivatives | |
| WO2002072527A3 (de) | 1-butansäurederivate wie z.b. carbomethoxypropionylcyanid oder leflunomidderivate und deren therapeutische anwendung | |
| AU2002333074A1 (en) | Enantiomers of n-(2,6-dimethylphenyl)-1-propyl-2-piperidinocarboxamide; its pharmaceutical compositions and processes of making them |